Our commitment in numbers
years of experience and heritage
Phase 2/3 clinical trials1
patient-years of human safety data from post-marketing sources2
invested in R&D activities, facilitates and infrastructure3
peer-reviewed publications4
institutions collaborated with as part of research5
Creating a bright future for prescription cannabis-based medicines
Our CEO Justin Gover takes a whistle stop tour through everything GW Pharmaceuticals, from our company vision to how we’ve grown over recent years, our main areas of research and how we foster scientific excellence. But most importantly, how we’ve listened to patients throughout this journey.
Find out more
Our CEO Justin takes a whistle stop tour through everything GW Pharmaceuticals, from our company vision to how we’ve grown over recent years, our main areas of research and how we foster scientific excellence. But most importantly, how we’ve listened to patients throughout this journey.
Investing in GW Pharmaceuticals
Find out more about investment
If you are an existing shareholder or potential investor, visit our global corporate site to stay up to date with share price, news and other relevant information.
Visit global corporate site-
Data on file (Total number of phase 2-3 clinical trials – >60) – VV-MED-12392.
-
Data on file (The level of human safety estimated patient-years – >135,000) – VV-MED-12269.
-
Data on file (Total investment globally – >£1.3bn) – VV-MED-12367.
-
Data on file (Number of peer reviewed publications – >100) – VV-MED-12883.
-
Date on file (Total number of institutions collaborated with via our research – >1,300) – VV-MED-12315.